Editor, leitor
374
edições
Alterações
→Referências
1. Lee, AG. Neuromyelitis Optica/Myelin Oligodendrocytic Glycoprotein. Neuro-ophthalmology Virtual Education Library: NOVEL. Web Site Available at https://collections.lib.utah.edu/ark:/87278/s60w348v.
2. Morrow M, Wingerchuk D. Neuromyelitis optica. J Neurophthalmol. 2012;32(2):154-166.
3. Matiello M, Jacob A, Wingerchuk D, Weinshenker B. Neuromyelitis optica. Curr Opin Neurol. 2007;20(3):255-260.
4. de Seze J. Neuromyelitis optica. Arch Neurol. 2003;60(9):1336-1338.
5. Simon K, Schmidt H, Loud S, Ascherio A. Risk factors for multiple sclerosis, neuromyelitis optica, and transverse myelitis. Mult Scler. 2014;21(6):703-709.6.
6. Wingerchuk D. Evidence for humoral autoimmunity in neuromyelitis optica. Neurol Res. 2006;28(3):348-353.
7. Wingerchuk D, Banwell B, Bennett J, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177-189.
8. Patterson S, Goglin S. Neuromyelitis optica. Rheum Dis Clin North Am. 2017;43(4):579-591.
9. Romeo A, Segal B. Treatment of neuromyelitis optica spectrum disorders. Curr Opin Rheumatol. 2019;31(3):250-255.
10. Pearce J. Neuromyelitis optica. Spinal Cord. 2005;43(11):631-634.
11. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol. 2010;17(8):1019-1032.
12. Cree B, Bennet J, Kim H, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352-1363.
13. Pittock S, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614-625.
14. Watanabe S, Misu T, Miyazawa I, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult Scler. 2007;13(8):968-974.